Source comparison
TB-500 Research Hormonal Health Considerations: Protocol Design Comparison
Baseline Requirements Injury markers, inflammation panels TSH, free T3/T4, reverse T3, cortisol (AM/PM), IGF-1, SHBG, testosterone Endocrine profiling eliminates 60–70% of confounding variables in TB-500 studies. The cost is negligible compared to invalidated
This comparison does not assign a generated winner or score.
- Baseline Requirements
- Injury markers, inflammation panels
- TSH, free T3/T4, reverse T3, cortisol (AM/PM), IGF-1, SHBG, testosterone
- Endocrine profiling eliminates 60–70% of confounding variables in TB-500 studies. The cost is negligible compared to invalidated datasets
- Monitoring Intervals
- Endpoint measurement only
- Week 2, Week 4, Week 8, 6-week post-protocol
- TB-500's hormonal effects peak at different intervals. Single-endpoint measurement misses the modulation curve entirely
- Dose Adjustment Triggers
- Fixed protocol regardless of response
- TSH elevation >20%, free T3 drop >15%, cortisol suppression >25% below baseline
- Adaptive dosing based on individual endocrine response increases data validity without compromising the experimental question
- Washout Period
- None or minimal (1–2 weeks)
- Minimum 6 weeks before endpoint hormone measures
- Thyroid axis and HPA sensitivity normalize slowly. Inadequate washout guarantees carryover effects
- Control Group Design
- Saline placebo only
- Saline placebo + thyroid support control arm
- TB-500's thyroid modulation is consistent enough to justify a third control arm receiving thyroid support without TB-500